Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. PCI Biotech Holding ASA's cash to debt ratio for the quarter that ended in Jun. 2025 was 48.29.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, PCI Biotech Holding ASAcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2025.
The historical rank and industry rank for PCI Biotech Holding ASA's Cash-to-Debt or its related term are showing as below:
OSL:PCIB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 47.98 Med: 208.76 Max: No Debt
Current: 48.29
During the past 13 years, PCI Biotech Holding ASA's highest Cash to Debt Ratio was No Debt. The lowest was 47.98. And the median was 208.76.
OSL:PCIB's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.72
vs OSL:PCIB: 48.29
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
PCI Biotech Holding ASA Cash-to-Debt Related Terms
PCI Biotech Holding ASA Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
OSL:PCIB vs VRTX, REGN, ALNY: Cash-to-Debt Comparison
For the Biotechnology subindustry, PCI Biotech Holding ASA's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PCI Biotech Holding ASA Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where PCI Biotech Holding ASA's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PCI Biotech Holding ASA (OSL:PCIB) has a Cash-to-Debt of 48.29 as of Jun. 2025. This is 77% below median its historical median of 208.76. Over the past decade, PCI Biotech Holding ASA's Cash-to-Debt has ranged from 47.98 to 10,000.00.
Is PCI Biotech Holding ASA's Cash-to-Debt too high?
PCI Biotech Holding ASA's current Cash-to-Debt of 48.29 is 77% below median its 10-year median of 208.76. Over the past 10 years, this metric has ranged from a low of 47.98 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.72. PCI Biotech Holding ASA's value of 48.29 is 618.6% above this industry median. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does PCI Biotech Holding ASA's Cash-to-Debt compare to VRTX and REGN?
PCI Biotech Holding ASA's Cash-to-Debt of 48.29 can be compared against companies in the Biotechnology industry. The industry median Cash-to-Debt is 6.72. PCI Biotech Holding ASA's value of 48.29 is 618.6% above this benchmark. Historically, PCI Biotech Holding ASA's own Cash-to-Debt has ranged from 47.98 to 10,000.00 over the past decade. While the company's 10-year median is 208.76 vs. the industry median of 6.72, PCI Biotech Holding ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.72, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PCI Biotech Holding ASA's current Cash-to-Debt of 48.29 is 618.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PCI Biotech Holding ASA's current Cash-to-Debt is 48.29, which is 77% below median its own 10-year median of 208.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (OSL:PCIB) has a current Cash-to-Debt of 48.29. The current Cash-to-Debt is 48.29, which is 77% below median its 10-year median of 208.76 and 618.6% above the Biotechnology industry median of 6.72. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current Cash-to-Debt is 48.29 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
6GF Score
Get the complete analysis for OSL:PCIB
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:PCIB has been successfully added to your 
